



Cite this: *Chem. Commun.*, 2015, 51, 8070

Received 16th January 2015,  
Accepted 2nd April 2015

DOI: 10.1039/c5cc00448a

www.rsc.org/chemcomm

## Diastereoselective synthesis of *P*-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction†

F. Pertusati\* and C. McGuigan

The first copper-catalysed diastereoselective synthesis of *P*-chiral phosphoramidate prodrugs (ProTides) is reported. This procedure allows the synthesis of diastereomeric-enriched mixtures of ProTides. Application of this methodology to the asymmetric phosphorylation of purine and pyrimidine nucleoside analogues is presented.

Nucleoside analogues (NAs) are an important class of molecules accounting for half of all antiviral drugs currently on the market and a number of anticancer agents that are widely used.<sup>1</sup> All NAs require phosphorylation to be active. Unfortunately, many nucleoside analogues are not phosphorylated effectively *in vivo*, and thus their therapeutic potential is often quite limited. Using various approaches, the ionizable phosphate group can be masked by derivatization, thus generating prodrugs with increased lipophilicity.<sup>2</sup> Among different prodrug strategies is the ProTide (pronucleotide) approach, which we introduced. The ProTide of a nucleoside phosphate is a phosphoramidate prodrug consisting of an amino acid ester, promoiety linked *via* a P–N bond to a nucleoside aryl phosphate. The ProTide technology was successfully and extensively applied to a wide variety of nucleoside phosphates.<sup>3</sup> Several leading pharmaceutical companies have applied this technology for anti-viral and anticancer treatments. Gilead, has just launched on the market its anti-HCV ProTide, Sofosbuvir **1** (PSI-7977)<sup>4</sup> whereas Nucana Biomed has taken to trial a gemcitabine ProTide, (NUC-1031, **2**)<sup>5</sup> for patients with advanced solid tumours (Fig. 1). Gilead has exploited this technology to create an advanced anti-HIV drug (GS 7340), an acyclic phosphonate analogue now in Phase III clinical trial.<sup>6</sup> To further highlight the importance of phosphoramidates we note that this functional group is also present in important biological active molecules such as Phosmidosine<sup>7</sup> and Agrocin 84.<sup>8</sup> Two different synthetic strategies for the preparation of phosphoramidate prodrugs are commonly used.<sup>9</sup> In the first, *tert*-butyl magnesium chloride (*t*BuMgCl) is used as a base in the coupling reaction between a nucleoside and the




Fig. 1 Structure of important phosphoramidate prodrugs.

phosphorochloridate bearing the desired promoieties. In the second approach, *N*-methyl imidazole (NMI) is used in place of *tert*-butyl magnesium chloride to promote the coupling. According to the two above-mentioned non-stereoselective procedures, phosphoramidate prodrugs are generally prepared as 1 : 1 mixtures of diastereoisomers ( $R_p$  and  $S_p$ ) because of the newly formed chiral center at the phosphorus atom.

Although stereoisomers have the same chemical structure they may exhibit differences in their pharmacology, toxicology, pharmacokinetics and metabolism. Up to now the phosphoramidate prodrugs cannot be easily prepared in the form of single diastereoisomers because of the lack of control of the stereochemistry at the phosphorus center during the synthesis. When it has been possible to separate the diastereoisomers, the biological activity has often been found dependent on the configuration on the phosphorus atom.<sup>10</sup> For example,  $S_p$  diastereoisomer of the GS7340 is 10 fold more potent against HIV than the  $R_p$  diastereoisomer.<sup>10a</sup> Likewise, in HCV replicon assay  $R_p$  and  $S_p$  (more lipophilic) isomers of Sofosbuvir produced HCV activity with  $EC_{50}$  values of 7.5  $\mu$ M and 0.42  $\mu$ M respectively, thus demonstrating approximately 18 fold difference in activity between the two diastereoisomers.<sup>10b</sup> This has lead Gilead to launch Sofosbuvir as a single diastereoisomer, at considerable difficulty and expense. To select the optimal isomer for clinical development, the two single diastereoisomers of 1'-cyano-2'-*C*-methyl 4-aza-7,9-dideaza adenosine phosphoramidate, were profiled separately. The  $S_p$  isomer was found 6-fold more potent in the replicon assay and two times more efficient in the triphosphate formation in primary human hepatocytes.<sup>10c</sup> Finally, we were also able to demonstrate that phosphoramidates<sup>3a,b</sup> and

School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edwards VII Avenue, CF10 3NB, Cardiff, Wales, UK. E-mail: pertusati1@cf.ac.uk

† Electronic supplementary information (ESI) available: Full experimental details, characterization data and copies of NMR spectra, HPLC traces. See DOI: 10.1039/c5cc00448a



phosphonoamidates<sup>3f</sup> diastereoisomers are processed at different rates in enzymatic assay by carboxypeptidase.

Separation of diastereoisomers by crystallization proved to be an inefficient method to use especially at the end of a multistep synthesis such as in the case of Sofosbuvir (a crystal of pure diastereoisomer was necessary). Chromatographic separation is often impossible or in general is a very difficult task to achieve, where reverse-phase chromatography provided successful results only in few cases.<sup>11</sup> A multistep approach to obtain ProTides in a diastereoselective fashion has also been developed by the Meier group, using a chiral auxiliary on the phosphoramidating reagent.<sup>12</sup> This methodology still requires the synthesis and chromatographic purification of the chiral auxiliary, which is generally unstable and cannot readily be isolated or recycled. This method is also limited by modest yields and was only documented on a nucleoside substrate lacking competing 2',3'-hydroxyl groups. Ross and co-workers<sup>13</sup> developed another synthetic method in which a diastereomerically pure phosphoramidating agent bearing a *p*-nitrophenyl or pentafluorophenyl as leaving groups was used. However, these reagents require purification by non-conventional supercritical fluid chromatography coupled with expensive chiral stationary phases. According to our experience they are also unstable and decompose easily, with racemization of the phosphorus stereocenter occurring. These features make all these methods not very efficient and especially high-priced, time consuming and hard to scale up. We were in search of a catalytic methodology that will allow generation of the ProTide motif in a diastereoisomeric fashion on a variety of biologically active molecules. Screening the literature, we came across with the work of Jones<sup>14</sup> who developed a simple and effective method for the catalytic phosphorylation of alcohols using a chlorophosphate as phosphorylating agent in the presence of titanium catalyst. Since the common synthetic route toward ProTides implies the use of chlorophosphoroamidates<sup>9</sup> (analogous to Jones chlorophosphate) we decided to test the possibility to yield ProTides with this approach having the intention next to tune the procedure to our advantage for the achievement of their diastereoselective synthesis. 2'-C-methyl-6-O-methyl guanosine **3** and **4a** were selected respectively as model nucleoside and as phosphate source.<sup>15</sup> The synthesis of the resulting phosphoramidate **5a** ( $R_p:S_p$  1:1 mixture) which reached phase two clinical trials against HCV virus, has been previously reported.<sup>15</sup> When we treated a THF solution of **3** with phosphochloridate **4a** in the presence of 0.2 equivalent of titanium chloride at room temperature, **5a** was obtained in low yield (12%) and without any diastereoselectivity as revealed by RP-HPLC analysis of the crude reaction mixture (entry 1, Table 1). Not at all satisfied with the result achieved we turned our attention to another Jones report<sup>16</sup> on the phosphoryl transfer from chiral *N*-phosphoryl-5,5-diphenyl oxazolidinone to alcohol under copper(II) triflate catalysis. Since in these studies the phosphorylation was reported to be successful on two examples of nucleosides, we decided to evaluate the catalytic activity of  $\text{Cu}(\text{OTf})_2$  in the synthesis of ProTide **5a**. We reacted nucleoside **3** with chloridate **4a** in the presence of 0.2 equivalent of  $\text{Cu}(\text{OTf})_2$ , 1.5 equivalent of triethylamine and 0.1 equivalent of *N,N'*-ethylene bis-(benzaldimine) (BEN) as metal ligand in THF solution at r.t. The desired product **5a** was obtained after 12 hours in 14% yield with a diastereomeric ratio 1:2.5


Table 1 Screening of different conditions

Entry	$\text{MX}_n$ (equiv.)	Base	Solvent	Conversion to <b>5a</b> <sup>a</sup> (%)	$R_p/S_p$ d.r. <sup>a</sup>
1	$\text{TiCl}_4$	$\text{NET}_3$	THF	12	1:2.5
2 <sup>c</sup>	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	THF	14	1:2.5
3	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	THF	37 (28) <sup>b</sup>	1:6.2
4	$\text{Cu}(\text{OTf})_2$	DBU	THF	5	1:3.3
5	$\text{Cu}(\text{OTf})_2$	DMAP	THF	4	1:2.5
6	$\text{Cu}(\text{OTf})_2$	NMI	THF	1	1:1
7	$\text{Cu}(\text{OTf})_2$	<i>i</i> -Pr <sub>2</sub> NH	THF	34	1:3
8	$\text{Cu}(\text{OTf})_2$	DIPEA	THF	47	1:2.5
9	$\text{Cu}(\text{OTf})_2$	—	THF	0	—
10	$\text{Yb}(\text{OTf})_3$	$\text{NET}_3$	THF	20	1:2
11	$\text{Fe}(\text{OTf})_3$	$\text{NET}_3$	THF	15	1:1.7
12	$\text{La}(\text{OTf})_3$	$\text{NET}_3$	THF	20	1.1:1
13	AgOTf	$\text{NET}_3$	THF	0	—
14	$\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$	$\text{NET}_3$	THF	40	1:2.5
15	CuI	$\text{NET}_3$	THF	22	1:3.2
16	$\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$	$\text{NET}_3$	THF	39	1:2
17	$\text{Cu}(\text{SO}_4)_2 \cdot \text{H}_2\text{O}$	$\text{NET}_3$	THF	10	1:3.8
18	CuOAc	$\text{NET}_3$	THF	9	1:5
19	—	$\text{NET}_3$	THF	0	—
20	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	Ethylene glycol	0	—
21	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	1,4 Dioxane	38	1:2.3
22	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	DME	14	1:5
23	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	$\text{CH}_3\text{CN}$	Traces	1
24	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	Toluene	Traces	1:1.5
25	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	Pyridine	NR	—
26	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	$\text{CHCl}_3$	Traces	1:1.8
27	$\text{Cu}(\text{OTf})_2$	$\text{NET}_3$	$\text{CH}_2\text{Cl}_2$	Traces	1:1.6
28	<b>Cu(OTf)<sub>2</sub></b>	<b>DIPEA</b>	<b>DME</b>	<b>40 (35)<sup>b</sup></b>	<b>1:8</b>

Reaction conditions: **3** 100 mg,  $\text{MX}_n$  0.2 equiv.; **4a** 1 equiv.; solvent 10 mL; base 1.5 equivalent; ambient temperature, 12 h.<sup>a</sup> Determined by RP-HPLC analysis of the crude mixture.<sup>‡</sup> <sup>b</sup> Isolated yield. <sup>c</sup> *N,N'*-Ethylene bis-benzaldimine, (BEN) used as ligand (2 mol%).

(RP-HPLC of crude mixture) in favour of the  $S_p$  isomer (Table 1, entry 2). Intrigued by the first indication of diastereoselectivity we decided to investigate the importance of the presence of BEN as metal ligand. When BEN was excluded from the reaction mixture, ProTide **5a** was obtained in 37% yield and in a 1:7  $R_p:S_p$  diastereomeric ratio (RP-HPLC) (Scheme 1, Table 1, entry 3). The yield was moderate but the diastereoisomeric excess was striking. Encouraged by these results we proceeded to further investigate the reaction conditions in order to find those optimal in terms of conversion and diastereoselectivity. A comprehensive screen of different parameters such as base, metal catalyst and solvent were thus performed (Table 1).


First, the nature of the base was probed (Table 1, entries 3–9). It can be observed that heterocyclic bases such as DBU, DMAP and NMI (Table 1, entries 3–5), were ineffective in promoting the reaction and returned the desired compounds only in traces amount. Most of the other bases screened were efficient in terms of product yield, with the best results obtained with alkyl amines. When the reaction yield was considered, diisopropyl ethylamine (DIPEA) was the best

Scheme 1 Synthesis of **5a** under transition metal catalysed conditions.


amine yielding the phosphoramidate in 47% yield even if with a poor diastereomeric ratio (Table 1, entry 8). The best diastereomeric ratio was instead obtained with  $\text{NEt}_3$  in absence of ligand (Table 1, entry 3). It is interesting to note that no reaction occur in absence of the base (Table 1, entry 9). Because of these results triethylamine was selected as standard base for further screenings. Several metal salts were also evaluated (Table 1, entries 10 and 19). Since the absence of metal ligand seems to be beneficial to the reaction we decided to assess all these metal salts under ligand-free conditions. We began our investigation by screening ytterbium, iron, and lanthanum triflates. In all these cases **5a** was formed in low yield and poor diastereoselectivity. Interestingly, the use of lanthanum triflate, in contrast with all other metal triflates, although in minimum amount, led to the inversion of the diastereoselectivity slightly in favour of  $R_p$  isomer. To evaluate the effect of the oxidation state of the copper as well as the effect of the counter ion on the outcome of the reaction we screened also other copper salts. Table 1 report some of the results obtained.  $\text{Cu}(\text{OTf})_2$  was found to be the most suitable catalyst (Table 1, entry 3). Increasing the catalyst loading to 1 equivalent did not affect either the yield or diastereoselectivity. Our control experiment without catalyst yielded no product **5a** (Table 1, entry 19).

Finally, an assessment of the effect of the reaction medium on stereoselectivity and yield was performed (Table 1, entries 20–28). The use of ethereal solvents (except ethylene glycol) provided synthetically useful quantities of **5a** maintaining a certain degree of diastereoselectivity. On the contrary, alkyl halide and aromatics solvents as well as pyridine and acetonitrile were less successful, yielding only traces of the desired phosphoramidate product **5a**. Since in the base screening DIPEA was providing the best results in terms of yield we decided to assess DIPEA in combination with DME (Table 1, entry 28). To our delight in this conditions phosphoramidate **5a** was obtained in 40% yield and in a 1 : 8.3  $R_p/S_p$  d.r. as assessed by RP-HPLC analysis of the crude reaction mixture (Fig. 2). **5a** ( $R_p/S_p$  d.r. 1 : 8) was isolated by column chromatography in 35% yield, and its identity was confirmed by comparison with literature data.<sup>‡</sup>

The optimum reaction time was found in all cases to be 8–12 h, with lower conversion being observed with shorter reaction times. Variation of reaction temperature did not improve our results. Optimal conditions were found with  $\text{Cu}(\text{OTf})_2$  (0.2 equiv.), DIPEA (1.5 equiv.) in DME at room temperature for 12 h. The nature of the phosphorochloridate on the reaction outcome was then investigated (Scheme 2 and Table 2).



**Fig. 2** (A) HPLC traces of crude reaction mixture (Table 1, entry 28). HPLC conditions: 90 : 10  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  to 0 : 100  $\text{H}_2\text{O}/\text{CH}_3\text{CN}$  in 30 min. Flow =  $1 \text{ mL min}^{-1}$ ;  $\lambda = 280 \text{ nm}$ ; (B)  $^{31}\text{P}$ NMR ( $\text{CD}_3\text{OD}$ , 202 MHz) of **5a** ( $R_p : S_p$  d.r. = 1.2 : 8.8); (C)  $^{31}\text{P}$ NMR ( $\text{CD}_3\text{OD}$ , 202 MHz) of **5a** ( $R_p : S_p$  d.r. = 1 : 1).



**Scheme 2** Synthesis of phosphoramidates **5a–e** under transition metal catalysed conditions.


**Table 2** Screening of phosphorochloridates **4a–e**

Entry	Cpds	R	R <sub>1</sub>	R <sub>2</sub>	Conversion to <b>5a–e</b> <sup>a</sup> (%)	$R_p/S_p$ d.r. <sup>a</sup>
1	<b>4a</b>	$\text{CH}_3$	Naph	$\text{CH}_2t\text{Bu}$	40 (38) <sup>b</sup>	1 : 8.3
2	<b>4b</b>	$\text{CH}_3$	Ph	$\text{CH}_2t\text{Bu}$	54 (27) <sup>b</sup>	1 : 3
3	<b>4c</b>	$\text{CH}_3$	Naph	Bn	72 (66) <sup>b</sup>	1 : 6
4	<b>4e</b>	$\text{CH}_3$	Naph	$\text{CH}(\text{CH}_3)_2$	18 (12) <sup>b</sup>	1 : 5.4
5	<b>4d</b>	$\text{CH}(\text{CH}_3)_2$	Naph	Bn	43 (35) <sup>b</sup>	1 : 7.5

Reaction conditions: **3** 100 mg,  $\text{Cu}(\text{OTf})_2$  0.2 equiv.; **4a–e** 1 equiv.; DME 20 mL; DIPEA 1.5 equivalent; r.t., 12 h. <sup>a</sup> Determined by RP-HPLC of the crude mixture. <sup>b</sup> Isolated yield.

From the data in Table 2 it appears immediately clear that bulky substituents on the phosphochloridate partner exert a certain effect on the stereoselectivity. In fact, high diastereoselectivity is obtained with neopentyloxy-*L*-alanyl phosphorochloridate **4a** bearing a naphthyl group as aryloxy moiety, whereas a dramatic decrease in diastereoselectivity is observed with **4b** bearing the less bulky phenyl group (Table 2, entries 1 vs. 2). Moreover, if the naphthyloxy phosphorochloridate **4c** affords the phosphoramidate **5b** with a moderate diastereoisomeric ratio, the analogue phosphochloridate **4d** bearing the more sterically hindered *L*-valinyl benzyl ester yielded **5d** with an improved diastereoselectivity (Table 2 entries 3 vs. 5). Moderate diastereoselectivity was also obtained for **5e** starting from phosphochloridate **4e**. Compounds **5a–e** were all isolated by column chromatography on silica gel and fully characterized (see ESI<sup>†</sup>). Finally, it is noteworthy to highlight that in all the above reactions, the 5' phosphoramidate is formed exclusively ( $^1\text{H-NMR}$  and MS analysis) despite the fact that two OH groups are not protected. This constitutes a great synthetic advantage over other available methods since it avoids tedious protection–deprotection steps typical of nucleoside chemistry.

Having a successful protocol in hand its application to other nucleosides was investigate. Given our interest in the anticancer field we decided to apply this protocol to Clofarabine **6** and Nelarabine **7**. The results are collected in Scheme 3. Phosphoramidate **9a** was



**6** R =  $\text{NH}_2$ ; R<sub>1</sub> = Cl; R<sub>2</sub> = F

**7** R =  $\text{OCH}_3$ ; R<sub>1</sub> =  $\text{NH}_2$ ; R<sub>2</sub> = OH

**8a** R =  $\text{NH}_2$ ; R<sub>1</sub> = Cl; R<sub>2</sub> = F; d.r. = 1 : 1.5 ( $R_p : S_p$ ) 26%

**9a** R =  $\text{OCH}_3$ ; R<sub>1</sub> =  $\text{NH}_2$ ; R<sub>2</sub> = OH; d.r. = 3.5 : 1 70%

**Scheme 3** Scope of purine nucleosides, ProTides **8a** and **9a**. Isolated yield after column chromatography.




Scheme 4 Synthesis of **11e** under transition metal catalysed conditions.

Table 3 Screening of reaction conditions

Entry	MX <sub>n</sub>	Base	Solvent	Conversion to <b>11e</b> <sup>a</sup> (%)	d.r. <sup>a</sup>
1	Cu(OTf) <sub>2</sub>	DIPEA	DME	42	1 : 1
2	Yb(OTf) <sub>3</sub>	DIPEA	DME	35 <sup>c</sup>	1 : 1.7
3	Fe(OTf) <sub>3</sub>	NET <sub>3</sub>	THF	Traces	—
4	La(OTf) <sub>3</sub>	NET <sub>3</sub>	THF	50	1 : 2
5	Cu(OAc) <sub>2</sub>	DIPEA	DME	Traces	—
6	CuSO <sub>4</sub>	NET <sub>3</sub>	THF	60	1 : 2.8
7	<b>CuOAc</b>	<b>DIPEA</b>	<b>DME</b>	<b>35</b>	<b>1 : 6.3</b>
8	CuI	NET <sub>3</sub>	THF	41 (28) <sup>b</sup>	1 : 2.1
9	CuCl	NET <sub>3</sub>	THF	53	1 : 1.5
10	Cu(CF <sub>3</sub> CO <sub>2</sub> ) <sub>2</sub>	DIPEA	DME	60	1 : 4.2
11	Cu(OTf)·C <sub>6</sub> H <sub>6</sub>	DIPEA	THF	40	1 : 2.2
12	(MeCN) <sub>4</sub> ·CuOTf	NET <sub>3</sub>	THF	60	1 : 2.4

Reaction conditions: **10** 100 mg, **4a** 1 equiv.; solvent 20 mL. <sup>a</sup> Determined by RP-HPLC of the crude mixture. <sup>b</sup> Isolated yield. <sup>c</sup> 3'-O-regioisomer was observed.

obtained with an excellent conversion (70% isolated yield) and remarkably with opposite diastereoselectivity (d.r. = 3.5 : 1).

To further expand the scope of the present methodology and especially because the recent approval of the anti-HCV drug Sofosbuvir (as single diastereoisomer)<sup>3</sup> we decided to apply our protocol to pyrimidine nucleosides. 2'-Deoxy-2'-fluorouridine **10** was selected as model nucleoside (Scheme 4). Disappointingly, when **10** was reacted with phosphorochloridate **4e** under the optimized conditions, the phosphoramidate **11e** was recovered with a moderate conversion (38% by crude mixture HPLC analysis) with no remarkable diastereoselectivity (Table 3, entry 1). This prompted us to investigate further the reaction conditions in case of pyrimidine nucleosides.

Cu(OTf)<sub>2</sub> under a variety of conditions (solvent, base, etc.) was unproductive, returning the desired phosphoramidate **11e** in poor diastereoselective manner. Similar results were obtained screening other metal triflates (Table 3, entries 2–4). We therefore returned our attention to other copper salts-complexes. The results are collected in Table 3. Copper(i) acetate proved to be the best catalyst in terms of diastereoselectivity returning **11e** in 35% yield and 1 : 6.3 d.r. (Table 3, entry 7).§ The use of Cu(CF<sub>3</sub>CO<sub>2</sub>)<sub>2</sub> enhance the yield at the expense of the d.r. (Table 3, entry 10).

In conclusion we have developed a catalytic system capable of delivery the S<sub>p</sub> diastereoisomer of phosphoramidate prodrug of nucleoside analogues in a good diastereomeric enhanced fashion even if still in moderate yield. Cu(OTf)<sub>2</sub> proved to be the catalyst of choice for purine nucleosides whereas CuOAc appeared to be superior for pyrimidine nucleosides. This methodology can be successfully applied to a diverse set of nucleosides and phosphorochloridates. Further studies of this procedure will focus on improving the yield

while retaining or further enhancing the diastereoselectivity. Investigations for elucidating the mechanism are currently underway in our laboratories. Jonah Wilkes is acknowledged for the synthesis of one ProTide.

## Notes and references

‡ The absolute configuration of the S<sub>p</sub> isomer of **5a** was determined by comparison of the <sup>31</sup>P and <sup>1</sup>H NMR spectra of our sample with the <sup>31</sup>P and <sup>1</sup>H NMR spectra reported in the patent WO 2010/081082 where the absolute configuration at the phosphorus was assigned by vibrational circular dichroism.

§ Separation of the R<sub>p</sub> and S<sub>p</sub> **11e** diastereoisomers was achieved by preparative HPLC (see ESI†). Unfortunately, no suitable crystals for X-ray analysis were obtained.

- 1 L. P. Jordheim, D. Durantel, F. Zoulim and C. Dumontet, *Nat. Rev. Drug Discov.*, 2013, **12**, 447–464.
- 2 (a) S. J. Hecker and M. D. Erion, *J. Med. Chem.*, 2008, **51**, 2328–2345; (b) L. W. Peterson and C. E. McKenna, *Expert Opin. Drug Delivery*, 2009, **6**, 405–420.
- 3 (a) C. McGuigan, P. Murziani, M. Slusarczyk, B. Gonczy, J. Vande Voorde, S. Liekens and J. Balzarini, *J. Med. Chem.*, 2011, **54**, 7247–7258; (b) M. Slusarczyk, M. H. Lopez, J. Balzarini, M. Mason, G. W. Jiang, S. Blagden, E. Thompson, E. Ghazaly and C. McGuigan, *J. Med. Chem.*, 2014, **57**, 1531–1542; (c) K. S. Toti, M. Derudas, F. Pertusati, D. Sinnaeve, F. Van den Broeck, L. Margamuljana, J. C. Martins, P. Herdewijn, J. Balzarini, C. McGuigan and S. Van Calenbergh, *J. Org. Chem.*, 2014, **79**, 5097–5112; (d) C. McGuigan, M. Derudas, B. Gonczy, K. Hinsinger, S. Kandil, F. Pertusati, M. Serpi, R. Snoeck, G. Andrei, J. Balzarini, T. D. McHugh, A. Maitra, E. Akorli, D. Evangelopoulos and S. Bhakta, *Bioorg. Med. Chem.*, 2014, **22**, 2816–2824; (e) W. Wu and R. F. Borch, *Mol. Pharmacol.*, 2006, **3**, 451–456; (f) W. Wu, J. Sigmond, G. J. Peters and R. F. Borch, *J. Med. Chem.*, 2007, **50**, 3743–3746; (g) F. Pertusati, K. Hinsinger, A. S. Flynn, N. Powell, A. Tristram, J. Balzarini and C. McGuigan, *Eur. J. Med. Chem.*, 2014, **78**, 259–268.
- 4 “Approval of Sovaldi (Sofosbuvir) tablets for the treatment of chronic hepatitis C”. FDA. 7 Dec 2013. Retrieved 9 June 2014.
- 5 <http://clinicaltrials.gov/ct2/show/NCT01621854?term=nuc1031&rank=3>.
- 6 <http://clinicaltrials.gov/ct2/show/NCT01497899?term=gs7340&rank=3>.
- 7 D. R. Phillips, M. Uramoto, K. Isono and J. A. McCloskey, *J. Org. Chem.*, 1993, **58**, 854–859.
- 8 M. E. Tate, P. J. Murphy, W. P. Roberts and A. Kerr, *Nature*, 1979, **280**, 697.
- 9 M. Serpi, K. Madela, F. Pertusati and M. Slusarczyk, Synthesis of nucleotide prodrugs using the proTide approach, in *Curr. Protoc. Nucleic Acid Chem.*, John Wiley & Sons, Inc., 2013, vol. 53, pp. 15.5.1–15.5.15.
- 10 (a) M. K. H. Chapman, E. Priske, J. Rohloff, M. Sparacino, T. Terhorst and R. Yu, *Nucleosides, Nucleotides Nucleic Acids*, 2001, **20**, 621–625; (b) M. J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, S. Rachakonda, P. G. Reddy, B. S. Ross, P. Wang, H.-R. Zhang, S. Bansal, C. Espiritu, M. Keilman, A. M. Lam, H. M. M. Steuer, C. Niu, M. J. Otto and P. A. Furman, *J. Med. Chem.*, 2010, **53**, 7202–7218; (c) A. Cho, L. Zhang, J. Xu, R. Lee, T. Butler, S. Metobo, V. Aktoudianakis, W. Lew, H. Ye, M. Clarke, E. Doerffler, D. Byun, T. Wang, D. Babusis, A. C. Carey, P. German, D. Sauer, W. Zhong, S. Rossi, M. Fenaux, J. G. McHutchison, J. Perry, J. Feng, A. S. Ray and C. U. Kim, *J. Med. Chem.*, 2013, **57**, 1812–1825.
- 11 (a) N. Mespilet, Y. Saito, P. Morin and L. A. Agrofoglio, *J. Chromatogr. A*, 2003, **983**, 115–124; (b) C. J. Allender, K. R. Brain, C. Ballatore, D. Cahard, A. Siddiqui and C. McGuigan, *Anal. Chim. Acta*, 2001, **435**, 107–113.
- 12 (a) J. B. C. Arbelo Roman and C. Meier, *J. Med. Chem.*, 2010, **53**, 7675; (b) C. Arbelo Román, P. Wasserthal, J. Balzarini and C. Meier, *Eur. J. Org. Chem.*, 2011, 4899.
- 13 P. G. Reddy, B.-K. Chun, H.-R. Zhang, S. Rachakonda, B. S. Ross and M. J. Sofia, *J. Org. Chem.*, 2011, **76**, 3782–3790.
- 14 S. Jones and D. Selitsianos, *Org. Lett.*, 2002, **4**, 3671–3673.
- 15 C. McGuigan, K. Madela, M. Aljarah, A. Gilles, A. Brancala, N. Zonta, S. Chamberlain, J. Vernachio, J. Hutchins, A. Hall, B. Ames, E. Gorovits, B. Ganguly, A. Kolykhalov, J. Wang, J. Muhammad, J. M. Patti and G. Henson, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 4850–4854.
- 16 S. Jones and C. Smanmoo, *Org. Lett.*, 2005, **7**, 3271–3274.

